Healthcare PE has lost its performance edge, with the most recent vintage now trailing the broader asset class.
According to PitchBook’s H1 2026 Healthcare Funds Report, North American and European healthcare PE funds from the 2021-2023 vintages posted a 10.2% pooled IRR, trailing the 12% across all PE, marking the first cohort in which healthcare PE returns have significantly fallen behind the broader market.
Specialist PE funds outperformed the most in the 2012-2014 vintages, when healthcare PE’s 26.8% pooled IRR outpaced all PE’s 14.5% by more than 12 percentage points.
The premium has been volatile since, briefly recovering in the 2018-2020 vintages before turning negative.
Ben Zercher, senior analyst, biotech and pharma at PitchBook, said specialists had a clear edge in the early 2010s, when the sector was less crowded, and quality assets were available at reasonable prices. That advantage has narrowed as competition has increased.
“Generalist firms built dedicated healthcare teams, and more capital chased the same deals,” Zercher said, adding that the most recent vintages were also deployed around the 2021 peak, when entry valuations were elevated. However, he cautioned that those funds “are still early in their life, so their returns are far from final.”
Despite the trend, healthcare PE captured an all-time high of 6.1% of total PE capital raised in H1, driven largely by several large closes. Blackstone closed Blackstone Life Sciences VI at $6.3 billion in March, while Patient Square Capital closed its $4.4 billion second fund in May.
Latest Research
Anthropic: The IPO and Why $1.42 Trillion Holds
Those two funds alone accounted for two-thirds of the $16.2 billion healthcare PE specialists raised in H1, according to the report. Just 11 funds closed in the half, putting 2026 on track for a nearly 50% drop in fund count from last year
“LPs aren’t walking away from the sector; rather, capital is concentrating in fewer, larger funds, with managers who have a clear thematic strategy rather than sector focus alone. Many healthcare specialists have spent the past several years building those capabilities,” Zercher added.
Recent News
European fintech loses its Series A-B valuation crown
‘Disciplined and selective': Nvidia evaluates investment approach
Learn about our editorial standards.